For more ideas and analysis from Michael Burke and John Gray in Investors Intelligence, click here.
One reason: a 17, 000-patient analysis from Sweden that shows an increased risk of death.
Click here for updates and more in-depth analysis from Bernie Schaeffer and Chris Johnson.
Click here for more recommendations and analysis from Bill Martin, and to learn more about FindProfit.
We all recognize that we cannot treat this retrosoective analysis from Duke as gold-standard evidence.
FORBES: Why The New Dendreon Analysis Does Matter -- And Why It Doesn't
Click here for updates and more in-depth analysis from Matt Ragas and Bill Martin.
Click here for more information and analysis from David Kliff or to subscribe to Diabetic Investor.
Click here for more investing ideas and analysis from Jack Adamo in Insiders Plus.
For updates and more in-depth analysis from Gerald and Marvin Appel, please click here.
Click here to get more ideas and analysis from Jim Collins or subscribe to OTC Insight.
AtheroGenics never presented its original promised result, an analysis from the Montreal Heart Institute.
Click here for more recommendations and analysis from Kenneth Reid in Spear's Security Industry Analyst.
For updates and more in-depth analysis from Kelley Wright and Joseph McKittrick, click here.
There will also be expert analysis from BBC football pundits Alan Hansen and Mark Lawrenson.
Click here for more information and analysis from Richard Lehmann or to subscribe to ISA ETF Investor.
Click here for more commentary and analysis from John Buckingham, and to subscribe to The Prudent Speculator.
For updates and more in-depth analysis from Ken Kam and the Marketocracy M100, please click here.
Click here for more information and analysis from John Buckingham and to subscribe to The Prudent Speculator.
Overall, agitation or psychiatric symptoms made up 2% of in-flight medical emergencies, according to analysis from the UPSM.
For more information and analysis from Yiannis Mostrous, check out Growth Engines or Wall Street Winners.
Click here for more recommendations and analysis from Yiannis Mostrous, and to learn more about Personal Finance newsletter.
Click here for more information and analysis from Steve Todd and to learn more about the Todd Market Forecast.
Initially, GSK withheld the internal analysis from the FDA, but in 2006, the company informed CDER of the findings.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
Click here for more information and analysis from Ken Kam and the M100 and to subscribe to Marketocracy Marketscope.
For further analysis from Ken Kam and to subscribe to Marketscope, the journal of the Marketocracy M100, click here.
Click here for more information and analysis from Jordan Kimmel, and to learn more about the Magnet Investing Report.
For updates and more in-depth analysis from David Fried, please click here.
For updates and more in-depth analysis from Curtis Hesler, please click here.
Read latest news and analysis from BBC News on Lords reform here.
For more ideas and analysis from Dan Sullivan in The Chartist, click here.
应用推荐